Arcutis Biotherapeutics, Inc.

ARQT Nasdaq SEC CIK 1787306
Follow Arcutis Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $143.9M +45.1% vs same quarter last year
Net income $8.8M +18.8% vs same quarter last year
EPS, diluted $0.06 +0% vs same quarter last year
Operating cash flow $18.9M +1177.4% vs same quarter last year
Revenue by quarter
$71.4M
$65.8M
$81.5M
$99.2M
$129.5M
$105.4M
$129.9M
$143.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$376.1M−$16.1M
FY24$196.5M−$140M
FY23$59.6M−$262.1M
FY22$3.7M−$311.5M
FY21$0−$206.4M
FY20$0−$135.7M
FY19-−$42M
FY18-−$19.3M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−10000%−7500%−5000%−2500%0%2500%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2590.2%−3.3%−4.3%
FY2490.3%−65.3%−71.3%
FY2391.6%−404.5%−439.8%
FY2279.5%−8183%−8449.8%
FY21---
FY20---
FY19---
FY18---
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$6.3M
FY24−$112.3M
FY23−$247.5M
FY22−$258M
FY21−$175.6M
FY20−$113.4M
FY19−$43.1M
FY18−$14.1M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Arcutis Biotherapeutics
  • Healthcare median
−10000%−7500%−5000%−2500%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearArcutis BiotherapeuticsHealthcare median
FY25−4.3%−30.6%
FY24−71.3%−47%
FY23−439.8%−58%
FY22−8449.8%−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%